Nasdaq GlobeNewswire

Appian Expands Deployment Options

Del

Low-Code Platform for Digital Transformation Certified for Deployment on Microsoft Azure; Providing Customers with Extended Deployment Options

RESTON, Va., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Appian (NASDAQ:APPN), a leading Low-Code and Business Process Management platform provider, today announced that organizations can now deploy its digital transformation platform on Microsoft Azure IaaS. This combination of technologies brings Appian's powerful process management and fast low-code development to Azure's Infrastructure as a Service (IaaS), allowing customers to benefit from Appian and Azure in their digital business transformation initiatives. In addition, this extends the deployment options currently provided to Appian customers, helping them build an environment that best suits their security, regulatory, and compliance needs.

Appian customers have complete control over the platform scaling using Azure's native cloud architecture. Appian has made a comprehensive deployment design guide for deploying Appian on Azure available on the Appian Community at https://community.appian.com

"We are focused on providing our customers with the flexibility to deploy the Appian platform in environments that work best for their needs," said Malcolm Ross, VP of Product, Appian. "As a leader in low-code and business process management, our clients select us because building custom applications is intuitive and easy in our platform. We've seen demand from our customers to leverage the platform within Microsoft Azure, their preferred IaaS solution, making Appian on Azure a natural choice."

Andrea Carl, director, Commercial Communications, Microsoft Corp. said, "We are pleased to see Appian benefit from the global scale and breadth of cloud services of Microsoft Azure. Azure, combined with Appian's expertise in process management and development, supports our mutual customers as they migrate workflows to the cloud."

This expansion also benefits Appian's global partner ecosystem. Now strategic partners, such as KPMG, can provide the Appian digital transformation platform to customers deploying on Azure - further extending options for clients worldwide.

"Given the strength of our alliances with both Appian and Microsoft, this enhanced relationship will provide a powerful digital transformation platform well-suited for solving our client's business problems," said Jerry Iacouzzi, Advisory principal, KPMG. "Effective strategies for cloud migrations are top of mind for CIOs, and the combination of KPMG and Appian's expanded deployment capabilities on Microsoft Azure will allow us to support clients across the globe as they quickly - and securely - create new innovative solutions for their business in the cloud."

Currently, Appian works closely with Microsoft in several other areas. This includes the integration of the Appian platform with Microsoft Dynamics 365, Microsoft SharePoint as well as Microsoft Office 365.

About Appian
Appian provides a leading low-code software development platform that enables organizations to rapidly develop powerful and unique applications. The applications created on Appian's platform help companies drive digital transformation and competitive differentiation. For more information, visit www.appian.com.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements. All statements contained in this press release other than statements of historical facts, including statements regarding the future size of the low-code platforms market and the benefits that such platforms offer to users, are forward-looking statements. The words "anticipate," believe," "continue," "estimate," "expect," "intend," "may," "will" and similar expressions are intended to identify forward-looking statements. Appian has based these forward-looking statements on its current expectations and projections about future events and financial trends that Appian believes may affect its financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks and uncertainties, including the risks and uncertainties associated with market adoption of low-code solutions to drive digital transformation, risks and uncertainties related to the estimates and assumptions used to calculate the size of the low-code platforms market, risks and uncertainties related to the publication of reports about Appian's business by industry analysts, and the additional risks and uncertainties set forth in the "Risk Factors" section of Appian's prospectus filed pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended, on May 26, 2017, and subsequent reports that Appian has filed with the Securities and Exchange Commission.  Moreover, Appian operates in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for Appian's management to predict all risks, nor can Appian assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements Appian may make. In light of these risks, uncertainties and assumptions, Appian cannot guarantee future results, levels of activity, performance, achievements or events and circumstances reflected in the forward-looking statements will occur. Appian is under no duty to update any of these forward-looking statements after the date of this press release to conform these statements to actual results or revised expectations, except as required by law. 

For Information Contact:
Nicole Greggs
Director of Media Relations
+1 703-260-7868
nicole.greggs@appian.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Appian Corporation via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

World Conference on Lung Cancer Monday Press Conference: Clinical Research Results and Gender Differences in Lung Cancer Survival24.9.2018 20:26Pressemelding

TORONTO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- At today’s press conference at the International Association for the Study of Lung Cancer’s (IASLC’s) 19th World Conference on Lung Cancer (WCLC), conference co-president Dr. Andrea Bezjak, M.D., FRCPC, MSc, professor in the Departments of Radiation Oncology and Health Policy, Management and Evaluation at the University of Toronto and staff radiation oncologist at Princess Margaret Cancer Centre, summarized the wide-ranging study topics presented in today’s conference, from significant clinical research findings to gender differences in lung cancer survival. IMpower132 study shows atezolizumab in combination with carboplatin and pemetrexed improves survival in Stage IV non-squamous NSCLC Recent findings from the IMpower132 study, presented by Vassiliki A. Papadimitrakopoulou, M.D., chief of the Section of Thoracic Medical Oncology at MD Anderson Cancer Center, demonstrate that the use of atezolizumab in combination with carboplatin as first-l

Bombardier CRJ Series Certified for Higher Maintenance Intervals24.9.2018 18:00Pressemelding

MONTREAL, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Bombardier Commercial Aircraft announced today that the Federal Aviation Agency (FAA) has granted approval for the maintenance intervals escalation of the CRJ700, CRJ900 and CRJ1000 aircraft. The line maintenance interval (A-check) is extended to 800 flight hours, and the heavy maintenance interval (C-check) at 8,000 flight hours. “With the longest maintenance intervals on the regional jet market, the CRJ aircraft family continues to deliver more value to operators, along with its excellent reliability and its proven outstanding operational capability”, said Charles Comtois, Head of CRJ Series Program, Bombardier Commercial Aircraft. “We are thrilled that our operators are benefitting from our continuous improvement mindset as with this evolution, the CRJ Series operators can now take advantage of 14 per cent less maintenance days, meaning more days of revenue flying.” The maintenance intervals have doubled since the launch of the CRJ aircra

Mitratech Launches Latest TeamConnect ELM Innovations at Interact24.9.2018 16:01Pressemelding

Full Integration of TAP Workflow Automation, New Business Intelligence Module and Deeper MS Office Integration Enhance Collaboration and Reporting AUSTIN, Texas, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Mitratech released the next version of TeamConnect at Interact, the company’s customer-focused annual event in Austin. The latest version of the award-winning ELM platform now includes: Full Integration with TAP Workflow Automation Business Intelligence reporting Deeper Microsoft® Office integration Today, TeamConnect integrates with TAP Workflow Automation and redefines every aspect of data analytics and reporting through the TeamConnect Business Intelligence (BI) module. With the addition of the TAP Workflow Automation Platform recently acquired in April, Mitratech’s TeamConnect platform can now bring people, processes, and information together like never before, by leveraging TAP’s easy-to-use workflow automation engine to extend TeamConnect’s reach across the entire enterprise. TAP was des

Colliers International Appoints Christopher Galvin to Its Board of Directors24.9.2018 16:00Pressemelding

TORONTO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Colliers International Group Inc. (NASDAQ and TSX: CIGI) (“Colliers”) today announced the appointment of Mr. Christopher Galvin to its Board of Directors, effective immediately. Mr. Galvin previously served as the Chairman and co-founder of Harrison Street Real Estate Capital LLC, one of the largest real estate investment firms dedicated to the education, healthcare and storage sectors. Colliers acquired a 75% interest in Harrison Street earlier this year. Mr. Galvin presently serves as Chairman or board member of Uniquesoft, LLC, Velocidata, evolve24, Three Ocean Partners and MCR-Aerodyne, Inc. Additionally, Mr. Galvin is a member of the Executive Committee of Northwestern University’s Board of Trustees, and the Boards of Trustees of the American Enterprise Institute, the Legion D’honneur, and Tsinghua University School of Economics Management Advisory Council, among others. Mr. Galvin has previously served in a variety of executive leadersh

Seclore Offers the First Open Data-Centric Security Platform24.9.2018 15:00Pressemelding

Easily leverage best-of-breed data protection solutions and existing Enterprise systems for an automation-first approach to data protection and tracking MILPITAS, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Seclore, providers of the industry’s first browser-based Rights Management solution, today announced the release of Seclore’s Data-Centric Security Platform (DCSP). A first-of-its kind platform, it is designed to give customers an open, integrated and automated Data-Centric Security approach to discover, identify, protect and track sensitive data. The automation and agility of the platform enables organizations to remove the limitations of point solutions while increasing the security of sensitive data. At the core of the Seclore DCSP, is the Seclore Unified Policy Manager, the central engine for orchestrating policy management, identity federation, and usage data consolidation. Learn more about the Seclore Data-Centric Security Platform “As data grows exponentially and is stored and

XBiotech Announces Completion of U.S. Enrollment in Phase 2 Multicenter Study Evaluating Bermekimab in Patients with Hidradenitis Suppurativa24.9.2018 14:30Pressemelding

AUSTIN, Texas, Sept. 24, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that it had completed enrollment in the U.S. for its Phase 2, open label clinical study evaluating subcutaneous administration of bermekimab in patients with moderate to severe Hidradenitis Suppurativa (HS). Enrollment has exceeded the planned limit for the study in just over two months, significantly outpacing expectations. XBiotech plans to accept a limited number of additional patients in Europe prior to study completion. John Simard, Chairman & CEO of XBiotech, commented, “We are very pleased by the enrollment rate we have seen in this study. Patient availability has been well beyond what was predicted. I believe this speaks to the need for new treatment options for this debilitating disease. I want to thank all of the patients and clinical sites for their ongoing participation in this study.” The phase 2 study involves a 13-week treatment regimen. Two groups of patients are being treated

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom